PapersPMID:38594107
The Effects of L-Carnitine Supplementation on Weight Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Systematic Review and Dose-response Meta-Analysis of Randomized Controlled Trials.
- findings
- 3
- compound
- 1
- endpoints
- 3
(R)-carnitine- Study, every finding
- meta-analysis
- Dose studied, every finding
- per 1 g/d increment of l-carnitine (dose-response)
- Population, every finding
- Adults with type 2 diabetes in 21 randomized trials (2041 patients); dose-response estimate per 1 g/d
What moved
How to read these marks →“We found that every 1 g/d supplementation with l-carnitine significantly reduced body mass index (MD: -0.37 kg/m2, 95% CI: -0.59, -0.15; I2 =93%, n=13, GRADE=low), HbA1c (MD: -0.16%, 95% CI: -0.32, -0.01; I2 = 94%, n = 18, GRADE = moderate), and low-density lipoprotein cholesterol (MD: -0.11 mmol/L, 95% CI: -0.16, -0.05; I2 = 91%, n = 11, GRADE = high).”
- Decreases glycated haemoglobin (HbA1c)
very limited
- Effect
- −0.16 mean difference, 95% CI −0.32 to −0.01
- Decreases LDL cholesterol
very limited
- Effect
- −0.11 mean difference, 95% CI −0.16 to −0.05
- Decreases body mass index
very limitedreplicated ×2
- Effect
- −0.37 mean difference, 95% CI −0.59 to −0.15
Study record
- Design
- meta-analysis
- Species
- human
- Population
- adults with type 2 diabetes in randomized trials of l-carnitine supplementation
- Participants
- 2,041
- Comparator
- another dose / not stated in the paper
- Duration
- not reported
- Endpoints measured
- 8